It has been shown that selective PDE7 inhibition or dual PDE4/7 inhibition may provide a novel therapeutic approach for the treatment of chronic lymphocytic leukemia (CLL) by enhancing killing and increasing specificity for CLL cells (Zhang et al., 2008). The gene discussed is PDE4A; the disease is B-cell chronic lymphocytic leukemia.